Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.35 |
| ▸ | CA1 | P00915 | 8/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 4/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20698977 | 0.81 | CA2 (0.39) | CA2CA1CA9CA4CA12 | |
| SCHEMBL22021490 | 0.81 | CA2 (0.39) | CA2CA1CA9CA4CA12 | |
| SCHEMBL5511537 | 0.81 | CA2 (0.37) | CA2CA1CA9CA4CA12 | |
| SCHEMBL14166842 | 0.76 | NOS1 (0.41) | MEN1KMT2A | |
| SCHEMBL27692126 | 0.75 | FFAR2 (0.41) | ADORA3SLC6A3LOXL2 | |
| SCHEMBL2658629 | 0.75 | FFAR2 (0.36) | — | |
| SCHEMBL21963159 | 0.74 | CA2 (0.34) | CA2CA1CA9CA4CA12 | |
| SCHEMBL1939405 | 0.72 | CA2 (0.35) | CA2CA1CA9CA12ADORA3 | |
| SCHEMBL19475597 | 0.70 | CA2 (0.44) | CA2CA1CA9CA4CA12 | |
| SCHEMBL11119773 | 0.70 | CA2 (0.50) | CA2CA1CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119995-A1 | Inverse thiazolylamide derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-29 | — | — | US | claimed |
| US-20020119995-A1 | Inverse thiazolylamide derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119995-A1 | Inverse thiazolylamide derivatives | MAVS, DPP4, EIF2AK2 | CA2 2818/4885CA1 4807/4885CA9 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.